Company Overview
Phreesia, Inc. operates within the Healthcare sector specifically as a provider of Health Information Services, delivering an integrated SaaS-based software and payment platform designed to streamline operations for the healthcare industry in the United States and Canada. The company's core offerings include appointment scheduling systems that manage online appointments, reminders, and referral tracking, alongside registration solutions engineered to automate patient intake and data entry processes. This specialized technology infrastructure supports the administrative and operational needs of medical practices, facilitating efficient patient flow and reducing manual data entry burdens across the healthcare ecosystem. In terms of scale, Phreesia holds a market capitalization of $707.77M and generates annual revenue of $463.20M, supported by a workforce of 2082 employees. These financial metrics indicate that the company has established a significant operational footprint within its niche, possessing substantial cash reserves relative to its current revenue generation, which suggests a mature platform capable of sustaining operations while potentially scaling further.
Financial Health
The company reported revenue of $463.20M over the trailing twelve months, resulting in a net income of $-5,379,000 and an EBITDA of $14.42M. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and tax provisions currently exceed operating profits, indicating that the business is prioritizing expansion or investment in its technology platform over immediate profitability. Despite the net loss, the company maintains robust free cash flow of $33.37M, which signifies strong financial flexibility and the ability to fund operations, invest in research and development, or return capital to stakeholders without relying on external financing. The margin profile presents a complex picture with a gross margin of 68.2%, suggesting efficient cost of goods sold management, contrasted sharply by an operating margin of -46.7% and a profit margin of -1.2%, which highlight significant overhead costs consuming the majority of gross profits. On the balance sheet, Phreesia holds $439.85M in cash against $12.64M in debt, creating a highly conservative position further evidenced by a debt-to-equity ratio of 2.60, although the high debt-to-equity figure requires careful interpretation given the massive cash buffer that effectively neutralizes leverage risk. Liquidity is further supported by a current ratio of 2.44, indicating that current assets are more than double current liabilities, ensuring the company can comfortably meet its short-term obligations. Return on Equity stands at -1.9% and Return on Assets is -0.3%, metrics that reveal that management has not yet generated returns on the capital invested, reflecting the typical phase of a high-growth technology company where reinvestment rates are high and profitability has not yet materialized on a per-share or per-asset basis.
Valuation Assessment
Valuation multiples for Phreesia show a trailing P/E ratio of N/A due to the net loss, while the forward P/E is projected at 7.82, implying that the market anticipates a significant turnaround in earnings performance in the coming fiscal year. The price-to-book ratio is recorded at 2.21, indicating that the market values the company at a premium of roughly 121% over its book value, which often reflects investor confidence in the intangible assets and growth potential of the SaaS business model. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 1.53 and an EV/EBITDA of 19.95, suggesting the company is valued at a premium relative to its sales volume but with an enterprise value multiple that aligns with growth-stage software companies. The stock's price volatility is contextualized by a 52-week high of $32.76 and a 52-week low of $10.75, meaning the current price sits well within this historical range, reflecting market fluctuations driven by broader sector trends and specific company developments. The beta value of 0.72 indicates that Phreesia's stock price is less volatile than the broader market, moving with lower sensitivity to general market swings, which offers a degree of stability compared to high-beta technology stocks.
Growth & Income
Phreesia demonstrates impressive momentum with revenue growth of 45.7% year-over-year, while earnings growth is listed as N/A due to the company's current net loss status. This dynamic implies that the company is successfully scaling its top line much faster than it is currently able to convert those sales into bottom-line earnings, a common trajectory for early-stage technology firms reinvesting heavily in growth. As the company does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically available for reinvestment rather than distribution to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion coupled with a total absence of dividend income, positioning the company as a pure-play growth investment where returns are expected to be realized through future capital appreciation rather than current cash distributions.